<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report" xml:lang="en">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id>
      <journal-id journal-id-type="iso-abbrev">BMC Cancer</journal-id>
      <journal-title-group>
        <journal-title>BMC Cancer</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1471-2407</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">23714228</article-id>
      <article-id pub-id-type="pmc">3671182</article-id>
      <article-id pub-id-type="publisher-id">1471-2407-13-262</article-id>
      <article-id pub-id-type="doi">10.1186/1471-2407-13-262</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Activity of EGFR-tyrosine kinase and ALK inhibitors for <italic>EML4&#x2013;ALK</italic>-rearranged non&#x2013;small&#x2013;cell lung cancer harbored coexisting <italic>EGFR</italic> mutation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" id="A1">
          <name>
            <surname>Miyanaga</surname>
            <given-names>Akihiko</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>a-miyanaga@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A2">
          <name>
            <surname>Shimizu</surname>
            <given-names>Kumi</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>s9048@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A3">
          <name>
            <surname>Noro</surname>
            <given-names>Rintaro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>r-noro@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A4">
          <name>
            <surname>Seike</surname>
            <given-names>Masahiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>mseike@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A5">
          <name>
            <surname>Kitamura</surname>
            <given-names>Kazuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>kazu-k@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A6">
          <name>
            <surname>Kosaihira</surname>
            <given-names>Seiji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>say-cos@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A7">
          <name>
            <surname>Minegishi</surname>
            <given-names>Yuji</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>yminegis@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A8">
          <name>
            <surname>Shukuya</surname>
            <given-names>Takehito</given-names>
          </name>
          <xref ref-type="aff" rid="I7">7</xref>
          <email>tshukuya@juntendo.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A9">
          <name>
            <surname>Yoshimura</surname>
            <given-names>Akinobu</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <xref ref-type="aff" rid="I8">8</xref>
          <email>ay1004@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A10">
          <name>
            <surname>Kawamoto</surname>
            <given-names>Masashi</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <xref ref-type="aff" rid="I3">3</xref>
          <email>kawamoto@med.teikyo-u.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A11">
          <name>
            <surname>Tsuchiya</surname>
            <given-names>Shinichi</given-names>
          </name>
          <xref ref-type="aff" rid="I2">2</xref>
          <email>tuchiyan@nms.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A12">
          <name>
            <surname>Hagiwara</surname>
            <given-names>Koichi</given-names>
          </name>
          <xref ref-type="aff" rid="I4">4</xref>
          <email>hagiwark@saitama-med.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A13">
          <name>
            <surname>Soda</surname>
            <given-names>Manabu</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>msoda@jichi.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A14">
          <name>
            <surname>Takeuchi</surname>
            <given-names>Kengo</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>kentakeuchi-tky@umin.net</email>
        </contrib>
        <contrib contrib-type="author" id="A15">
          <name>
            <surname>Yamamoto</surname>
            <given-names>Nobuyuki</given-names>
          </name>
          <xref ref-type="aff" rid="I7">7</xref>
          <email>n.yamamoto@scchr.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A16">
          <name>
            <surname>Mano</surname>
            <given-names>Hiroyuki</given-names>
          </name>
          <xref ref-type="aff" rid="I5">5</xref>
          <email>hmano@jichi.ac.jp</email>
        </contrib>
        <contrib contrib-type="author" id="A17">
          <name>
            <surname>Ishikawa</surname>
            <given-names>Yuichi</given-names>
          </name>
          <xref ref-type="aff" rid="I6">6</xref>
          <email>ishikawa@jfcr.or.jp</email>
        </contrib>
        <contrib contrib-type="author" corresp="yes" id="A18">
          <name>
            <surname>Gemma</surname>
            <given-names>Akihiko</given-names>
          </name>
          <xref ref-type="aff" rid="I1">1</xref>
          <email>agemma@nms.ac.jp</email>
        </contrib>
      </contrib-group>
      <aff id="I1"><label>1</label>Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan</aff>
      <aff id="I2"><label>2</label>Division of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan</aff>
      <aff id="I3"><label>3</label>Department of Clinical Pathology, University Hospital, Mizonokuchi, Teikyo University School of Medicine, Kanagawa, Japan</aff>
      <aff id="I4"><label>4</label>Saitama Medical School Respiratory Organs Internal Medicine, Saitama, Japan</aff>
      <aff id="I5"><label>5</label>Division of Functional Genomics, Jichi Medical University, Tochigi, Japan</aff>
      <aff id="I6"><label>6</label>Division of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan</aff>
      <aff id="I7"><label>7</label>Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka, Japan</aff>
      <aff id="I8"><label>8</label>Department of Clinical Oncology, Tokyo Medical University Hospital, Tokyo, Japan</aff>
      <pub-date pub-type="collection">
        <year>2013</year>
      </pub-date>
      <pub-date pub-type="epub">
        <day>29</day>
        <month>5</month>
        <year>2013</year>
      </pub-date>
      <volume>13</volume>
      <fpage>262</fpage>
      <lpage>262</lpage>
      <history>
        <date date-type="received">
          <day>17</day>
          <month>1</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>22</day>
          <month>5</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>Copyright &#xA9; 2013 Miyanaga et al.; licensee BioMed Central Ltd.</copyright-statement>
        <copyright-year>2013</copyright-year>
        <copyright-holder>Miyanaga et al.; licensee BioMed Central Ltd.</copyright-holder>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0">
          <license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p>
        </license>
      </permissions>
      <self-uri xlink:href="http://www.biomedcentral.com/1471-2407/13/262"/>
      <abstract>
        <sec>
          <title>Background</title>
          <p>The <italic>EML4&#x2013;ALK</italic> (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene represents a novel molecular target in a small subset of non&#x2013;small&#x2013;cell lung cancers (NSCLCs). The <italic>EML4&#x2013;ALK</italic> fusion gene occurs generally in NSCLC without mutations in epidermal growth factor receptor <italic>(EGFR)</italic> and <italic>KRAS</italic>.</p>
        </sec>
        <sec>
          <title>Case presentation</title>
          <p>We report that a case of <italic>EML4&#x2013;ALK</italic>-positive NSCLC with <italic>EGFR</italic> mutation had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>We described the first clinical report of a patient with <italic>EML4&#x2013;ALK</italic>-positive NSCLC with <italic>EGFR</italic> mutation that had a response of stable disease to both single-agent EGFR-TKI and ALK inhibitor. <italic>EML4&#x2013;ALK</italic> translocation may be associated with resistance to EGFR-TKI, and EGFR signaling may contribute to resistance to ALK inhibitor in <italic>EML4&#x2013;ALK</italic>-positive NSCLC.</p>
        </sec>
      </abstract>
      <kwd-group>
        <kwd>EML4&#x2013;ALK</kwd>
        <kwd><italic>EGFR</italic> mutation</kwd>
        <kwd>Lung cancer</kwd>
      </kwd-group>
    </article-meta>
  </front>
  <body>
    <sec>
      <title>Background</title>
      <p>The <italic>EML4&#x2013;ALK</italic> (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion oncogene was recently identified as a novel genetic alteration in non-small-cell lung cancer (NSCLC) [<xref ref-type="bibr" rid="B1">1</xref>]. <italic>EML4&#x2013;ALK</italic> fusions have been detected in 2 to 7% of NSCLC patients. Patients harboring <italic>ALK</italic> rearrangements tend to be never and light smokers, have a history of adenocarcinoma, and be younger in age [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. In general, the <italic>EML4&#x2013;ALK</italic> fusion oncogene existed exclusively in NSCLC patients without the epidermal growth factor receptor (<italic>EGFR</italic>) gene mutation [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>].</p>
      <p>ALK inhibitors such as crizotinib are clinically effective in NSCLC patients harboring ALK rearrangements [<xref ref-type="bibr" rid="B9">9</xref>]. Crizotinib produced a high response rate and prolonged median progression-free survival among patients with ALK-positive NSCLC [<xref ref-type="bibr" rid="B9">9</xref>]. Crizotinib was recently approved by the US Food and Drug Administration and Japanese Ministry of Health, Labour and Welfare for the treatment of patients with advanced, ALK-rearranged NSCLC.</p>
      <p>In this paper, we report a patient with NSCLC with concomitant ALK rearrangement and <italic>EGFR</italic> mutation that had a response of stable disease to both an EGFR tyrosine kinase inhibitor (EGFR-TKI) and ALK inhibitor.</p>
    </sec>
    <sec>
      <title>Case presentation</title>
      <p>In December 2009, a 55-year-old female who had never smoked was noted to have left lung opacity on a routine chest X-ray. No significant previous medical history was reported. Computed tomography (CT) scan of the chest revealed a 1.5 &#xD7; 1.5 cm nodular lesion in the left upper lobe and hilar lymph node metastasis. Transthoracic needle biopsy histology revealed adenocarcinoma, and the histopathological subtype of the specimen was papillary adenocarcinoma with signet-ring cell components (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>A-<xref ref-type="fig" rid="F1">1</xref>C). The specimen was positive for periodic acid&#x2013;Schiff (PAS) (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>C). On immunohistochemical staining, the tumor cells were positive for thyroid transcription factor-1 (TTF-1) (Figure&#xA0;<xref ref-type="fig" rid="F1">1</xref>D). Laboratory findings were within normal range, except for the carcinoembryonic antigen (CEA) level of 158.0 ng/mL (normal range, 0 to 4.3 ng/mL) in the serum. She had multiple dorsal vertebra metastases (cT1N1M1b, stage IV).</p>
      <fig id="F1" position="float">
        <label>Figure 1</label>
        <caption>
          <p><bold>Histology of the primary tumour.</bold> (<bold>A</bold>) and (<bold>B</bold>) shows a papillary adenocarcinoma (hematoxylin and eosin 200&#xD7; magnification), (<bold>C</bold>) a mucin stain shows positive for both signet-ring and papillary morphology (PAS, 400&#xD7; magnification). <bold>(D)</bold> immunohistochemical analysis of lung adenocarcinoma specimens with <italic>EML4-ALK</italic> fusion using a monoclonal anti-TTF-1 antibody (200&#xD7; magnification).</p>
        </caption>
        <graphic xlink:href="1471-2407-13-262-1"/>
      </fig>
      <p>Analysis for <italic>EGFR</italic> gene mutation was performed using a cytological specimen by means of the peptide nucleic acid&#x2013;locked nucleic acid (PNA-LNA) polymerase-chain-reaction (PCR) clamp method as described previously [<xref ref-type="bibr" rid="B10">10</xref>,<xref ref-type="bibr" rid="B11">11</xref>]. The specimen showed a deletion in exon 19 (L747-A750del T751S). We collected mRNA from the same tumor specimens using Pinpoint Slide RNA Isolation System in order to clarify whether there was <italic>EML4&#x2013;ALK</italic> (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) fusion gene in each tumor. Reverse transcription polymerase-chain-reaction (RT-PCR) followed by direct sequencing confirmed the presence of <italic>EML4&#x2013;ALK</italic> variant 2 [<xref ref-type="bibr" rid="B1">1</xref>] (Figure&#xA0;<xref ref-type="fig" rid="F2">2</xref>). In addition, <italic>EML4&#x2013;ALK</italic> was identified by using fluorescent in situ hybridization (FISH) for <italic>ALK</italic> rearrangements (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>B) and was confirmed by immunohistochemistry for ALK expression in tumor [<xref ref-type="bibr" rid="B2">2</xref>] (Figure&#xA0;<xref ref-type="fig" rid="F3">3</xref>A).</p>
      <fig id="F2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>
            <bold>The sequence of the junction between </bold>
            <bold>
              <italic>EML4 </italic>
            </bold>
            <bold>exon 20 and </bold>
            <bold>
              <italic>ALK </italic>
            </bold>
            <bold>exon 20.</bold>
          </p>
        </caption>
        <graphic xlink:href="1471-2407-13-262-2"/>
      </fig>
      <fig id="F3" position="float">
        <label>Figure 3</label>
        <caption>
          <p><bold>Diagnosis of an EML4-ALK-positive non-small cell lung cancer.</bold> (<bold>A</bold>) Immunostaining for ALK protein expression in tumor cells. (<bold>B</bold>) The results of a break-apart FISH assay of tumor cells from a patient with rearrangement of the gene encoding <italic>ALK.</italic></p>
        </caption>
        <graphic xlink:href="1471-2407-13-262-3"/>
      </fig>
      <p>A platinum doublet was chosen as first line therapy according to existing treatment protocol in 2009. Four cycles of combination chemotherapy comprising cisplatin and pemetrexed was administered at 3-week intervals. She was judged as having a stable disease. After 7 months, spinal magnetic resonance imaging (MRI) revealed progression of the dorsal vertebra lesions. Therefore, EGFR-TKI was chosen as a 2nd-line therapy. She received gefitinib therapy at 250 mg/day administered orally for 2 months. CT imaging of the chest showed that the pulmonary nodule was not growing after gefitinib therapy, and the tumor marker levels had not changed. However, spinal MRI demonstrated growing dorsal vertebra metastases 2 months after the start of gefitinib therapy. The carcinoembryonic antigen (CEA) level increased from 117 ng/ml to 250 ng/ml. Therefore, the patient was judged as having progressive disease. After local radiation therapy with a total of 30 Gy for dorsal metastases, a second EGFR-TKI was chosen given the stable primary disease. She received another EGFR-TKI, erlotinib (150 mg/day), as 3<sup>rd</sup>-line therapy. After being progression-free for 3 months, spinal MRI revealed a growing thoracic vertebra metastasis. She received 4<sup>th</sup>-line treatment with 2 cycles of docetaxel (DTX). However, her disease progressed 6 months later. Finally, she received a targeted inhibitor of ALK. The patient initially had SD associated with a temporary decrease in the CEA level from 743 ng/ml to 520 ng/ml, but her disease progressed after 4 months of therapy. The ALK inhibitor treatment was ceased and full supportive care was given. All lines of therapy were well tolerated.</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>We presented a patient with NSCLC with concomitant ALK rearrangement and <italic>EGFR</italic> mutation that had a response of stable disease to both EGFR-TKI and ALK inhibitors. The presence of <italic>EML4&#x2013;ALK</italic> generally seems to be mutually exclusive of the presence of <italic>EGFR</italic> or <italic>KRAS</italic> mutations in NSCLC [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B7">7</xref>,<xref ref-type="bibr" rid="B8">8</xref>]. Previous reports showed twelve cases of <italic>EML4&#x2013;ALK</italic>-positive lung cancer with <italic>EGFR</italic> mutation [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B12">12</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Only one patient with harboring <italic>ALK</italic> translocation and EGFR mutation was treated by ALK inhibitor has been reported [<xref ref-type="bibr" rid="B17">17</xref>]. Lee et al. reported two ALK-positive and EGFR-mutant NSCLC patient who did not respond to EGFR-TKI but achieved a durable partial response to ALK inhibitor [<xref ref-type="bibr" rid="B17">17</xref>]. The present patient was a woman with no history of smoking. Her pathological diagnosis was papillary adenocarcinoma with a signet-ring cell component, which was consistent with the previously reported characteristics of <italic>EML4&#x2013;ALK</italic>-positive lung adenocarcinoma except for the <italic>EGFR</italic> mutation status [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B6">6</xref>]. It was reported that EGFR-TKI therapy among patients with advanced NSCLC and <italic>EGFR</italic> mutations revealed a response rate of more than 60% and progression-free survival of 9 to 14 months [<xref ref-type="bibr" rid="B11">11</xref>,<xref ref-type="bibr" rid="B18">18</xref>,<xref ref-type="bibr" rid="B19">19</xref>]. In addition, recent reports showed that ALK inhibition in NSCLC patients with the <italic>ALK</italic> rearrangement resulted in tumor shrinkage or stable disease in most patients [<xref ref-type="bibr" rid="B9">9</xref>]. Unfortunately, EGFR-TKI treatment was not effective in the tumor regression nor tumor marker level of present patient (disease might be controlled), but treatment with an ALK inhibitor resulted in SD with decreasing tumor markers. Therefore, this case showed that ALK rearrangement might be superior to EGFR mutation for the driver mutation.</p>
      <p>It was reported that <italic>EML4&#x2013;ALK</italic> fusion was associated with resistance to EGFR-TKIs [<xref ref-type="bibr" rid="B20">20</xref>]. Patients with NSCLC in the <italic>EML4&#x2013;ALK</italic> cohort and the wild type cohort showed similar response rates to platinum-based combination chemotherapy and no difference in overall survival [<xref ref-type="bibr" rid="B20">20</xref>]. Whereas <italic>EGFR</italic> mutations confer sensitivity to EGFR-TKIs, <italic>EML4&#x2013;ALK</italic> is strongly associated with resistance to EGFR-TKIs. In a previous case of concomitant <italic>EGFR</italic> mutation and <italic>ALK</italic> translocation, the patient presented the most durable response to an EGFR-TKI and was a case demonstrating no EML4<italic>&#x2013;</italic>ALK expression by immunohistochemistry with an <italic>EML4&#x2013;ALK</italic> rearrangement characterized by an isolated 3_ FISH signal [<xref ref-type="bibr" rid="B12">12</xref>]. Our patient presented a concurrent <italic>EML4-ALK</italic> rearrangement and ALK expression by immunohistochemistry; however, EGFR-TKI was not effective.</p>
      <p>Among patients with both <italic>EML4&#x2013;ALK</italic> rearrangement and <italic>EGFR</italic> mutation, <italic>in vitro</italic> studies showed that EGFR signaling can contribute to ALK inhibitor resistance in EML4<italic>&#x2013;</italic>ALK NSCLC [<xref ref-type="bibr" rid="B14">14</xref>]. In addition, these findings suggested that a cancer cell line that harbors a concurrent <italic>ALK</italic> rearrangement and an <italic>EGFR</italic> mutation would be expected to be resistant to both single agent ALK and EGFR inhibitors [<xref ref-type="bibr" rid="B14">14</xref>]. We suggest that the combination of both ALK and EGFR inhibitors as early-line treatment may represent an effective therapy for this subset of NSCLC patients.</p>
    </sec>
    <sec sec-type="conclusions">
      <title>Conclusions</title>
      <p>This is the first clinical report of a patient with <italic>EML4&#x2013;ALK</italic>-positive NSCLC with <italic>EGFR</italic> mutation that had a response of stable disease to both single-agent EGFR-TKI and ALK inhibitor. The <italic>EML4&#x2013;ALK</italic> fusion gene defines a new molecular subset of NSCLCs with distinct clinical and pathologic features. NSCLCs with <italic>ALK</italic> rearrangement are highly sensitive to ALK inhibition. However, EGFR signaling may contribute to ALK inhibitor resistance in <italic>EML4&#x2013;ALK</italic> NSCLC. Therefore, we suggest that this provides a translational opportunity whereby laboratory studies should be undertaken to understand the biological link between ALK rearrangement and <italic>EGFR</italic> mutation, with a view to establishing whether there is preclinical justification for using combination therapy for NSCLC with concomitant ALK rearrangement and <italic>EGFR</italic> mutation.</p>
    </sec>
    <sec>
      <title>Consent</title>
      <p>Written informed consent was obtained from the patient for publication of this case report and accompanying images.</p>
    </sec>
    <sec>
      <title>Abbreviations</title>
      <p>EML4: Echinoderm microtubule-associated protein-like 4; ALK: Anaplastic lymphoma kinase; NSCLC: Non-small cell lung cancer; EGFR: Epidermal growth factor receptor; TKI: Tyrosine kinase inhibitor; CT: Computed tomography; PAS: periodic acid&#x2013;Schiff; TTF-1: Thyroid transcription factor-1; PNA-LNA: Peptide nucleic acid&#x2013;locked nucleic acid; PCR: Polymerase chain reaction technique; FISH: Fluorescent in situ hybridization; SD: Stable disease; MRI: Magnetic resonance imaging (MRI); CEA: Carcinoembryonic antigen; RT-PCR: Reverse transcription polymerase chain reaction.</p>
    </sec>
    <sec>
      <title>Competing interests</title>
      <p>The authors declare that they have no competing interests.</p>
    </sec>
    <sec>
      <title>Authors&#x2019; contributions</title>
      <p>AM prepared the manuscript and the literature search; RN and MS reviewed and edited the manuscript; HM and AG corrected and revised the manuscript; KS, KK, SK, YM, MS and TS treated and observed the patient; MK and ST performed the histopathological, immunohistochemical examinations; and AY, KH, KT, NY and YI reviewed the manuscript. All authors read and approved of the final manuscript.</p>
    </sec>
    <sec>
      <title>Pre-publication history</title>
      <p>The pre-publication history for this paper can be accessed here:</p>
      <p>
        <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/13/262/prepub">http://www.biomedcentral.com/1471-2407/13/262/prepub</ext-link>
      </p>
    </sec>
  </body>
  <back>
    <sec>
      <title>Acknowledgements</title>
      <p>The authors wish to thank Mari Masuda for technical support in the sequence alignment.</p>
    </sec>
    <ref-list>
      <ref id="B1">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Soda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Enomoto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Takada</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yamashita</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Ishikawa</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Fujiwara</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Watanabe</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kurashina</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Hatanaka</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer</article-title>
          <source>Nature</source>
          <year>2007</year>
          <volume>448</volume>
          <issue>7153</issue>
          <fpage>561</fpage>
          <lpage>566</lpage>
          <pub-id pub-id-type="doi">10.1038/nature05945</pub-id>
          <pub-id pub-id-type="pmid">17625570</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B2">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Takeuchi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Soda</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Inamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Togashi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hatano</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Enomoto</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Takada</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yamashita</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Satoh</surname>
            <given-names>Y</given-names>
          </name>
          <article-title>Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts</article-title>
          <source>Clin Can Res</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>20</issue>
          <fpage>6618</fpage>
          <lpage>6624</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-1018</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B3">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Koivunen</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Mermel</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Zejnullahu</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Murphy</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Lifshits</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Holmes</surname>
            <given-names>AJ</given-names>
          </name>
          <name>
            <surname>Choi</surname>
            <given-names>HG</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Chiang</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>R</given-names>
          </name>
          <article-title>EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer</article-title>
          <source>Clin Can Res</source>
          <year>2008</year>
          <volume>14</volume>
          <issue>13</issue>
          <fpage>4275</fpage>
          <lpage>4283</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-08-0168</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B4">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mano</surname>
            <given-names>H</given-names>
          </name>
          <article-title>Non-solid oncogenes in solid tumors: EML4-ALK fusion genes in lung cancer</article-title>
          <source>Cancer Sci</source>
          <year>2008</year>
          <volume>99</volume>
          <issue>12</issue>
          <fpage>2349</fpage>
          <lpage>2355</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1349-7006.2008.00972.x</pub-id>
          <pub-id pub-id-type="pmid">19032370</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B5">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Wong</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Leung</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>So</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Tam</surname>
            <given-names>IY</given-names>
          </name>
          <name>
            <surname>Sihoe</surname>
            <given-names>AD</given-names>
          </name>
          <name>
            <surname>Cheng</surname>
            <given-names>LC</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>KK</given-names>
          </name>
          <name>
            <surname>Au</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>LP</given-names>
          </name>
          <name>
            <surname>Pik Wong</surname>
            <given-names>M</given-names>
          </name>
          <article-title>The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS</article-title>
          <source>Cancer</source>
          <year>2009</year>
          <volume>115</volume>
          <issue>8</issue>
          <fpage>1723</fpage>
          <lpage>1733</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.24181</pub-id>
          <pub-id pub-id-type="pmid">19170230</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B6">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Perner</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Wagner</surname>
            <given-names>PL</given-names>
          </name>
          <name>
            <surname>Demichelis</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Mehra</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Lafargue</surname>
            <given-names>CJ</given-names>
          </name>
          <name>
            <surname>Moss</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Arbogast</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Soltermann</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Weder</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Giordano</surname>
            <given-names>TJ</given-names>
          </name>
          <article-title>EML4-ALK fusion lung cancer: a rare acquired event</article-title>
          <source>Neoplasia</source>
          <year>2008</year>
          <volume>10</volume>
          <issue>3</issue>
          <fpage>298</fpage>
          <lpage>302</lpage>
          <pub-id pub-id-type="pmid">18320074</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B7">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Inamura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Takeuchi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Togashi</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Nomura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Ninomiya</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Okui</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Satoh</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Okumura</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Nakagawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Soda</surname>
            <given-names>M</given-names>
          </name>
          <article-title>EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers</article-title>
          <source>J Thorac Oncol</source>
          <year>2008</year>
          <volume>3</volume>
          <issue>1</issue>
          <fpage>13</fpage>
          <lpage>17</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e31815e8b60</pub-id>
          <pub-id pub-id-type="pmid">18166835</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B8">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shinmura</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kageyama</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Tao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Bunai</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Suzuki</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kamo</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Takamochi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Suzuki</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tanahashi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Niwa</surname>
            <given-names>H</given-names>
          </name>
          <article-title>EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas</article-title>
          <source>Lung Cancer</source>
          <year>2008</year>
          <volume>61</volume>
          <issue>2</issue>
          <fpage>163</fpage>
          <lpage>169</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2007.12.013</pub-id>
          <pub-id pub-id-type="pmid">18242762</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B9">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kwak</surname>
            <given-names>EL</given-names>
          </name>
          <name>
            <surname>Bang</surname>
            <given-names>YJ</given-names>
          </name>
          <name>
            <surname>Camidge</surname>
            <given-names>DR</given-names>
          </name>
          <name>
            <surname>Shaw</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Maki</surname>
            <given-names>RG</given-names>
          </name>
          <name>
            <surname>Ou</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Dezube</surname>
            <given-names>BJ</given-names>
          </name>
          <name>
            <surname>Janne</surname>
            <given-names>PA</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>DB</given-names>
          </name>
          <article-title>Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>363</volume>
          <issue>18</issue>
          <fpage>1693</fpage>
          <lpage>1703</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa1006448</pub-id>
          <pub-id pub-id-type="pmid">20979469</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B10">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Nagai</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Miyazawa</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Huqun</surname>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Udagawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kato</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Fukuyama</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yokote</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kanazawa</surname>
            <given-names>M</given-names>
          </name>
          <article-title>Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp</article-title>
          <source>Cancer Res</source>
          <year>2005</year>
          <volume>65</volume>
          <issue>16</issue>
          <fpage>7276</fpage>
          <lpage>7282</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-0331</pub-id>
          <pub-id pub-id-type="pmid">16105816</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B11">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Maemondo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Inoue</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Kobayashi</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Sugawara</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Oizumi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Isobe</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Gemma</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Harada</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Yoshizawa</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Kinoshita</surname>
            <given-names>I</given-names>
          </name>
          <article-title>Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</article-title>
          <source>N Engl J Med</source>
          <year>2010</year>
          <volume>362</volume>
          <issue>25</issue>
          <fpage>2380</fpage>
          <lpage>2388</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa0909530</pub-id>
          <pub-id pub-id-type="pmid">20573926</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B12">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Popat</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Vieira de Araujo</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Min</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Swansbury</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Dainton</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wotherspoon</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Lim</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Nicholson</surname>
            <given-names>AG</given-names>
          </name>
          <name>
            <surname>O'Brien</surname>
            <given-names>ME</given-names>
          </name>
          <article-title>Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib</article-title>
          <source>J Thorac Oncol</source>
          <year>2011</year>
          <volume>6</volume>
          <issue>11</issue>
          <fpage>1962</fpage>
          <lpage>1963</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e31822eec5e</pub-id>
          <pub-id pub-id-type="pmid">22005476</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B13">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tiseo</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Gelsomino</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Boggiani</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Bortesi</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Bartolotti</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Bozzetti</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Sammarelli</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Thai</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Ardizzoni</surname>
            <given-names>A</given-names>
          </name>
          <article-title>EGFR and EML4-ALK gene mutations in NSCLC: a case report of erlotinib-resistant patient with both concomitant mutations</article-title>
          <source>Lung Cancer</source>
          <year>2011</year>
          <volume>71</volume>
          <issue>2</issue>
          <fpage>241</fpage>
          <lpage>243</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2010.11.014</pub-id>
          <pub-id pub-id-type="pmid">21168933</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B14">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Sasaki</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Koivunen</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Ogino</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Yanagita</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Nikiforow</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Zheng</surname>
            <given-names>W</given-names>
          </name>
          <name>
            <surname>Lathan</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Marcoux</surname>
            <given-names>JP</given-names>
          </name>
          <name>
            <surname>Du</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Okuda</surname>
            <given-names>K</given-names>
          </name>
          <article-title>A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors</article-title>
          <source>Cancer Res</source>
          <year>2011</year>
          <volume>71</volume>
          <issue>18</issue>
          <fpage>6051</fpage>
          <lpage>6060</lpage>
          <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-11-1340</pub-id>
          <pub-id pub-id-type="pmid">21791641</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B15">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Tanaka</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hayashi</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Morimoto</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Taima</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Tanaka</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Shimada</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Kurose</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Takanashi</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Okumura</surname>
            <given-names>K</given-names>
          </name>
          <article-title>A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene</article-title>
          <source>BMC Cancer</source>
          <year>2012</year>
          <volume>12</volume>
          <issue>1</issue>
          <fpage>558</fpage>
          <pub-id pub-id-type="doi">10.1186/1471-2407-12-558</pub-id>
          <pub-id pub-id-type="pmid">23181703</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B16">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Kuo</surname>
            <given-names>YW</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>SG</given-names>
          </name>
          <name>
            <surname>Ho</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Shih</surname>
            <given-names>JY</given-names>
          </name>
          <article-title>Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation</article-title>
          <source>J Thorac Oncol</source>
          <year>2010</year>
          <volume>5</volume>
          <issue>12</issue>
          <fpage>2039</fpage>
          <lpage>2040</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181f43274</pub-id>
          <pub-id pub-id-type="pmid">21102267</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B17">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Lee</surname>
            <given-names>JK</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>TM</given-names>
          </name>
          <name>
            <surname>Koh</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>SH</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>DW</given-names>
          </name>
          <name>
            <surname>Jeon</surname>
            <given-names>YK</given-names>
          </name>
          <name>
            <surname>Chung</surname>
            <given-names>DH</given-names>
          </name>
          <name>
            <surname>Yang</surname>
            <given-names>SC</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YT</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>YW</given-names>
          </name>
          <article-title>Differential sensitivities to tyrosine kinase inhibitors in NSCLC harboring EGFR mutation and ALK translocation</article-title>
          <source>Lung Cancer</source>
          <year>2012</year>
          <volume>77</volume>
          <issue>2</issue>
          <fpage>460</fpage>
          <lpage>463</lpage>
          <pub-id pub-id-type="doi">10.1016/j.lungcan.2012.04.012</pub-id>
          <pub-id pub-id-type="pmid">22622260</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B18">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Fukuoka</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Wu</surname>
            <given-names>YL</given-names>
          </name>
          <name>
            <surname>Thongprasert</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Sunpaweravong</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Leong</surname>
            <given-names>SS</given-names>
          </name>
          <name>
            <surname>Sriuranpong</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Chao</surname>
            <given-names>TY</given-names>
          </name>
          <name>
            <surname>Nakagawa</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Chu</surname>
            <given-names>DT</given-names>
          </name>
          <name>
            <surname>Saijo</surname>
            <given-names>N</given-names>
          </name>
          <article-title>Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS)</article-title>
          <source>J Clin Oncol</source>
          <year>2011</year>
          <volume>29</volume>
          <issue>21</issue>
          <fpage>2866</fpage>
          <lpage>2874</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2010.33.4235</pub-id>
          <pub-id pub-id-type="pmid">21670455</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B19">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Mitsudomi</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Morita</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yatabe</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Negoro</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Okamoto</surname>
            <given-names>I</given-names>
          </name>
          <name>
            <surname>Tsurutani</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Seto</surname>
            <given-names>T</given-names>
          </name>
          <name>
            <surname>Satouchi</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Tada</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Hirashima</surname>
            <given-names>T</given-names>
          </name>
          <article-title>Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial</article-title>
          <source>Lancet Oncol</source>
          <year>2010</year>
          <volume>11</volume>
          <issue>2</issue>
          <fpage>121</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="doi">10.1016/S1470-2045(09)70364-X</pub-id>
          <pub-id pub-id-type="pmid">20022809</pub-id>
        </mixed-citation>
      </ref>
      <ref id="B20">
        <mixed-citation publication-type="journal">
          <name>
            <surname>Shaw</surname>
            <given-names>AT</given-names>
          </name>
          <name>
            <surname>Yeap</surname>
            <given-names>BY</given-names>
          </name>
          <name>
            <surname>Mino-Kenudson</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Digumarthy</surname>
            <given-names>SR</given-names>
          </name>
          <name>
            <surname>Costa</surname>
            <given-names>DB</given-names>
          </name>
          <name>
            <surname>Heist</surname>
            <given-names>RS</given-names>
          </name>
          <name>
            <surname>Solomon</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Stubbs</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Admane</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>McDermott</surname>
            <given-names>U</given-names>
          </name>
          <article-title>Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <issue>26</issue>
          <fpage>4247</fpage>
          <lpage>4253</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2009.22.6993</pub-id>
          <pub-id pub-id-type="pmid">19667264</pub-id>
        </mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
